We are live on
!
Find out more
AC
Armistice Capital Portfolio holdings
AUM
$5.62B
1-Year Est. Return
36.06%
This Fund
S&P 500
This Quarter
Est. Return
+13.99%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$7.33B
AUM Growth
+$796M
(+12%)
Cap. Flow
-$12M
Cap. Flow
% of AUM
-0.16%
Top 10 Holdings %
Top 10 Hldgs %
60.07%
Holding
377
New
123
Increased
61
Reduced
77
Closed
82
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$68.6M |
| 2 |
argenx
ARGX
|
+$55M |
| 3 |
Sanofi
SNY
|
+$50.7M |
| 4 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
+$50.5M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
+$42.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$48.6M |
| 2 |
Keurig Dr Pepper
KDP
|
+$45.5M |
| 3 |
Incyte
INCY
|
+$45.2M |
| 4 |
UnitedHealth
UNH
|
+$37.3M |
| 5 |
Campbell Soup
CPB
|
+$32M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.97% |
| 2 | Consumer Staples | 5.35% |
| 3 | Consumer Discretionary | 4.92% |
| 4 | Technology | 3.86% |
| 5 | Communication Services | 1.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Aligos Therapeutics
ALGS
$32.6M
| $4.54M | 0.06% |
+273,355
| New | +$4.7M |
|
127
Crocs
CROX
$6.46B
| $4.5M | 0.06% |
48,205
-35,155
| -42% | -$3.25M |
|
128
Choice Hotels
CHH
$4.94B
| $4.12M | 0.06% |
+36,356
| New | +$4.16M |
|
|
SYBX
129
DELISTED
Synlogic
SYBX
| $4.06M | 0.06% |
1,055,000
+455,126
| +76% | +$1.15M |
|
|
IMGN
130
DELISTED
Immunogen Inc
IMGN
| $3.99M | 0.05% |
+134,698
| New | +$2.68M |
|
131
Eledon Pharmaceuticals
ELDN
$266M
| $3.94M | 0.05% |
2,189,000
+365,000
| +20% | +$507K |
|
132
Cracker Barrel
CBRL
$1.29B
| $3.85M | 0.05% |
+50,000
| New | +$3.59M |
|
133
Gossamer Bio
GOSS
$86.6M
| $3.79M | 0.05% |
4,156,000
-800,000
| -16% | -$591K |
|
134
Dine Brands
DIN
$448M
| $3.72M | 0.05% |
+75,000
| New | +$3.56M |
|
|
IOBT
135
DELISTED
IO Biotech
IOBT
| $3.62M | 0.05% |
1,924,000
-224,000
| -10% | -$267K |
|
136
Rockwell Medical
RMTI
$28.8M
| $3.5M | 0.05% |
185,200
-96,500
| -34% | -$1.81M |
|
|
ALP
137
Alpha Compute
ALP
$4.33M
| $3.41M | 0.05% |
93,805
-4,600
| -5% | -$153K |
|
|
NARI
138
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $3.01M | 0.04% |
46,322
-54,410
| -54% | -$3.28M |
|
|
KA
139
DELISTED
Kineta, Inc. Common Stock
KA
| $3M | 0.04% |
825,792
-104,208
| -11% | -$392K |
|
140
RLJ Lodging Trust
RLJ
$1.81B
| $2.93M | 0.04% |
+250,000
| New | +$2.6M |
|
|
ZSQR
141
Z Squared Inc
ZSQR
$220M
| $2.76M | 0.04% |
176,000
+65,400
| +59% | +$1.45M |
|
142
Moleculin Biotech
MBRX
$2.64M
| $2.75M | 0.04% |
+8,553
| New | +$1.78M |
|
143
The Beachbody Company
BODI
$77.5M
| $2.7M | 0.04% |
+325,179
| New | +$3.48M |
|
|
STEX
144
Streamex Corp
STEX
$74.7M
| $2.66M | 0.04% |
+560,000
| New | +$2.32M |
|
145
Worksport
WKSP
$10.9M
| $2.54M | 0.03% |
+170,700
| New | +$2.71M |
|
|
CMRX
146
DELISTED
Chimerix, Inc.
CMRX
| $2.5M | 0.03% |
2,598,000
-274,000
| -10% | -$265K |
|
|
LGVN
147
Longeveron
LGVN
$24.5M
| $2.5M | 0.03% |
+183,600
| New | +$3.5M |
|
148
VistaGen Therapeutics
VTGN
$12.8M
| $2.46M | 0.03% |
+478,000
| New | +$1.81M |
|
149
Planet Fitness
PLNT
$4.17B
| $2.44M | 0.03% |
+33,461
| New | +$2.06M |
|
150
CAVA Group
CAVA
$7.31B
| $2.38M | 0.03% |
+55,436
| New | +$1.93M |
|
Similar funds
CRC
RMDI
F
EW
O
DSC
ACM
PI
Armistice Capital's Q4 2023 Portfolio in Review
As of Q4 2023, Armistice Capital held 377 positions worth $7.33B, up 12% from $6.53B the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Armistice Capital's Q4 2023 filing shows 123 new, 61 increased, 77 reduced and 82 closed positions. Its largest new stake was Sanofi: 1,036,000 shares worth $51.5M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $48.6M.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 34% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
- Armistice Capital's largest Q4 2023 buy was Sanofi: 1,036,000 shares worth $51.5M.
- Armistice Capital added most to GSK in Q4 2023, an estimated $68.6M increase.
- Armistice Capital's biggest Q4 2023 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $48.6M.
- Armistice Capital fully exited Keurig Dr Pepper in Q4 2023, selling an estimated $45.5M.
- Armistice Capital's ten largest holdings make up 60% of its $7.33B portfolio in Q4 2023.
- Armistice Capital opened 123 new positions and closed 82 in Q4 2023.
- Armistice Capital's portfolio value rose 12% quarter-over-quarter to $7.33B.
Based on Armistice Capital's 13F filing for Q4 2023, filed 13 Feb 2024.